ScoreWhy is Fennec Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 65.05%, the company declared Very Positive results in Mar 26
- NET SALES(Q) Highest at CAD 20.72 MM
- RAW MATERIAL COST(Y) Fallen by -0.52% (YoY)
- CASH AND EQV(HY) Highest at CAD 106.5 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 30.00%, its profits have risen by 51.6%
3
High Institutional Holdings at 64.97%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 3.35% over the previous quarter.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Fennec Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fennec Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fennec Pharmaceuticals, Inc.
24.17%
2.33
68.47%
S&P/TSX 60
20.36%
2.51
12.02%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
134.72%
EBIT Growth (5y)
10.74%
EBIT to Interest (avg)
-7.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.78
Sales to Capital Employed (avg)
2.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
64.97%
ROCE (avg)
0
ROE (avg)
18.98%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.74
EV to EBIT
-54.20
EV to EBITDA
-54.43
EV to Capital Employed
-130.48
EV to Sales
6.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-17.73%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
NET SALES(Q)
Highest at CAD 24.74 MM
RAW MATERIAL COST(Y)
Fallen by -6.73% (YoY
OPERATING PROFIT(Q)
Highest at CAD 2.44 MM
OPERATING PROFIT MARGIN(Q)
Highest at 9.86 %
PRE-TAX PROFIT(Q)
Highest at CAD 2.79 MM
NET PROFIT(Q)
Highest at CAD 2.73 MM
EPS(Q)
Highest at CAD 0.07
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Fennec Pharmaceuticals, Inc.
Net Sales
Highest at CAD 24.74 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Net Sales
At CAD 24.74 MM has Grown at 85.13%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Pre-Tax Profit
At CAD 2.79 MM has Grown at 163.93%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CAD MM)
Net Profit
At CAD 2.73 MM has Grown at 162.6%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CAD MM)
Operating Profit
Highest at CAD 2.44 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CAD MM)
Operating Profit Margin
Highest at 9.86 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CAD 2.79 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CAD MM)
Net Profit
Highest at CAD 2.73 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
EPS
Highest at CAD 0.07
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CAD)
Raw Material Cost
Fallen by -6.73% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
